JP2020507623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507623A5 JP2020507623A5 JP2019563680A JP2019563680A JP2020507623A5 JP 2020507623 A5 JP2020507623 A5 JP 2020507623A5 JP 2019563680 A JP2019563680 A JP 2019563680A JP 2019563680 A JP2019563680 A JP 2019563680A JP 2020507623 A5 JP2020507623 A5 JP 2020507623A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- peptide
- human
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 101000851054 Homo sapiens Elastin Proteins 0.000 claims 5
- 102000054289 human ELN Human genes 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000001766 physiological effect Effects 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019238A JP2024056838A (ja) | 2017-02-06 | 2024-02-13 | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154889.4 | 2017-02-06 | ||
| EP17154889 | 2017-02-06 | ||
| PCT/EP2018/052822 WO2018141969A1 (en) | 2017-02-06 | 2018-02-05 | Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019238A Division JP2024056838A (ja) | 2017-02-06 | 2024-02-13 | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507623A JP2020507623A (ja) | 2020-03-12 |
| JP2020507623A5 true JP2020507623A5 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| JP7438757B2 JP7438757B2 (ja) | 2024-02-27 |
Family
ID=57995050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563680A Active JP7438757B2 (ja) | 2017-02-06 | 2018-02-05 | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
| JP2024019238A Pending JP2024056838A (ja) | 2017-02-06 | 2024-02-13 | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019238A Pending JP2024056838A (ja) | 2017-02-06 | 2024-02-13 | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20200087374A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3577462B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7438757B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018215245B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3051293A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2927977T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201906939XA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018141969A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6982395B2 (ja) * | 2017-03-16 | 2021-12-17 | 三洋化成工業株式会社 | インターロイキン１０の産生量増加剤 |
| WO2019104391A1 (en) * | 2017-12-01 | 2019-06-06 | St Vincent's Institute Of Medical Research | Type 1 diabetes treatment |
| AU2020337111A1 (en) * | 2019-08-30 | 2022-03-31 | Biotempt B.V. | Q-ER peptide |
| JP6895148B1 (ja) * | 2020-03-31 | 2021-06-30 | クラシエホールディングス株式会社 | 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット |
| CN117106029A (zh) * | 2020-06-08 | 2023-11-24 | 深圳市图微安创科技开发有限公司 | 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途 |
| JP2023544832A (ja) * | 2020-10-08 | 2023-10-25 | ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー | １型糖尿病の治療および予防のための方法および組成物 |
| CN112345770A (zh) * | 2020-11-06 | 2021-02-09 | 苏州大学附属第一医院 | 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用 |
| KR102718109B1 (ko) * | 2021-10-01 | 2024-10-17 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
| AU2022359382A1 (en) * | 2021-10-05 | 2024-05-02 | Biotempt B.V. | Angiogenic control, preferably combined with glycaemic control. |
| EP4554672A1 (en) | 2022-07-12 | 2025-05-21 | Resiliun B.V. | Treating conditions with hypoglycemia associated with hyperinsulinemia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
| EP1578352A2 (en) * | 2002-03-27 | 2005-09-28 | University of Utah Research Foundation | Elastin prevents occlusion of body vessels by vascular smooth muscle cells |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| GB0323979D0 (en) * | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| GB0412174D0 (en) * | 2004-06-01 | 2004-06-30 | Creative Peptides Sweden Ab | Degradation-resistant analogues of pro-insulin c-peptide |
| WO2008118387A2 (en) * | 2007-03-23 | 2008-10-02 | Wayne State University | Erythrocyte atp-release modulators |
| EP2480888B1 (en) * | 2009-09-25 | 2016-11-30 | XOMA Technology Ltd. | Screening methods |
| CN104105966B (zh) * | 2012-02-01 | 2016-10-26 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
| EP2626704B1 (en) * | 2012-02-08 | 2015-11-18 | Mehmet Ali Soylemez | Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin |
| BR112014025189B1 (pt) * | 2012-04-12 | 2020-04-07 | Brahms Gmbh | métodos de predizer o risco de adquirir um evento adverso e de orientação de tratamento com antibióticos em um paciente com insuficiência cardíaca crônica estável |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| JP6430962B2 (ja) * | 2013-01-08 | 2018-11-28 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心血管系疾患発症リスクの予測的マーカーとしての成長ホルモンの空腹時レベル |
| EP2972339A1 (en) * | 2013-03-15 | 2016-01-20 | Health Diagnostic Laboratory, Inc. | Method of generating an index score for mbl deficiency to predict cardiodiabetes risk |
| CN104371003B (zh) * | 2013-08-15 | 2025-09-02 | 上海市第一人民医院 | 预防和治疗炎症的小分子多肽及其应用 |
| US20170138961A1 (en) * | 2014-03-21 | 2017-05-18 | Sanofi-Aventis Deutschland Gmbh | New markers for the assessment of the risk for development of a cardiovascular disorder |
-
2018
- 2018-02-05 SG SG11201906939XA patent/SG11201906939XA/en unknown
- 2018-02-05 EP EP18705844.1A patent/EP3577462B1/en active Active
- 2018-02-05 EP EP24170487.3A patent/EP4421088A3/en not_active Withdrawn
- 2018-02-05 US US16/483,717 patent/US20200087374A1/en not_active Abandoned
- 2018-02-05 AU AU2018215245A patent/AU2018215245B2/en active Active
- 2018-02-05 AU AU2018216033A patent/AU2018216033B2/en active Active
- 2018-02-05 CA CA3051293A patent/CA3051293A1/en active Pending
- 2018-02-05 CA CA3049738A patent/CA3049738A1/en active Pending
- 2018-02-05 EP EP18705843.3A patent/EP3570875B1/en active Active
- 2018-02-05 ES ES18705843T patent/ES2927977T3/es active Active
- 2018-02-05 WO PCT/EP2018/052822 patent/WO2018141969A1/en not_active Ceased
- 2018-02-05 JP JP2019563680A patent/JP7438757B2/ja active Active
- 2018-02-05 US US16/483,317 patent/US20220009988A1/en not_active Abandoned
- 2018-02-05 WO PCT/EP2018/052824 patent/WO2018141970A1/en not_active Ceased
- 2018-02-05 SG SG11201906943VA patent/SG11201906943VA/en unknown
-
2023
- 2023-05-01 US US18/310,188 patent/US20240027431A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019238A patent/JP2024056838A/ja active Pending
- 2024-11-26 US US18/960,532 patent/US20250123275A1/en active Pending